We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




New Multiple Sclerosis Test Delivers Rapid Results with Minimally Invasive Blood Draw

By LabMedica International staff writers
Posted on 10 Nov 2023
Print article
Image: The Elecsys NfL test has been granted FDA Breakthrough Device Designation (Photo courtesy of 123RF)
Image: The Elecsys NfL test has been granted FDA Breakthrough Device Designation (Photo courtesy of 123RF)

An estimated 2.8 million individuals globally live with multiple sclerosis (MS), with about 85% of these cases being relapsing-remitting multiple sclerosis (RRMS). Most RRMS patients eventually progress to secondary progressive multiple sclerosis (SPMS), characterized by a gradual decline in neurological function and increasing disability. Timely detection of disease activity is crucial for these patients, aiding both them and their physicians in making informed disease management decisions. Now, a new minimally invasive test can assist in detecting disease activity in adult MS patients, offering quick and valuable information for patients and caregivers, and enhancing decision-making for disease management.

Neurofilament Light Chain (NfL), a protein unique to neurons, serves as a sensitive marker of neuroaxonal damage. While NfL is naturally released from axons at low levels, this rate increases with age and in response to neuroaxonal damage. Consequently, abnormal and elevated levels of NfL can be detected in the cerebrospinal fluid and blood in various neurological disorders. Roche (Basel, Switzerland) has introduced the Elecsys NfL test, specifically targeting adults aged 18-55 with RRMS or SPMS. This test is designed to provide essential insights for managing MS. Elecsys NfL is engineered to enable laboratories to expand MS testing on the widely accessible, fully automated, and standardized Roche cobas instruments, ensuring reliable results.

While currently focused on MS, elevated NfL levels have also been observed in other neurodegenerative diseases, including Alzheimer's and Huntington's diseases, and in other neurological conditions. The Elecsys NfL test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), a significant advancement in Roche's efforts to enhance its diagnostics neurology portfolio. This follows the FDA's similar designation in July 2022 for Roche’s Elecsys Amyloid Plasma Panel, a novel tool aimed at early detection of Alzheimer’s disease. The FDA's recognition of Elecsys NfL underscores its potential impact, and once approved, the test will be globally accessible through the extensive network of 75,000 Roche instruments worldwide.

“Around 2.8 million people are estimated to live with multiple sclerosis.1 After diagnosis, many face challenges with managing their disease due to significant gaps in access to testing. This can lead to missed opportunities to detect disease progression in support of treatment optimization,” said Matt Sause, CEO of Roche Diagnostics. “We are excited about the potential Elecsys NfL has to improve outcomes for MS patients by offering a minimally invasive blood draw that can deliver rapid results.”

Related Links:
Roche 

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
D-Dimer Test
Epithod 616 D-Dimer Kit
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
H. pylori Test
QuickVue H. pylori Test

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.